The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Read­ing about John Car­roll’s pick of biotech’s most promis­ing star­tups has be­come a trea­sured tra­di­tion. If you ever get cu­ri­ous about pre­vi­ous class­es of the End­points 11, you can find all of them (plus a num­ber of our oth­er reg­u­lar spe­cials) here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER